Study on Rhenium Re 188 P2045 for Lung Cancer Patients Who Have Had or Refused Chemotherapy

Sponsor: Andarix Pharmaceuticals

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT00100256

Provider View

This clinical trial is testing the safety of a new drug, Rhenium Re 188 P2045, in patients with lung cancer who have either already received chemotherapy or have chosen not to. The study aims to find the highest dose that can be given without causing serious side effects.

Patient Parameters

Program Overview

The goal of this study is to find out the safest dose of an experimental drug called Rhenium Re 188 P2045 for treating lung cancer. Researchers will start by giving patients low doses of the drug and will carefully monitor them for any side effects. If the drug is well-tolerated, the dose will be gradually increased. The study also aims to see if the drug can help reduce lung cancer tumors.

Description

This study is focused on understanding the side effects of two drugs, Technetium Tc 99m P2045 and Rhenium Re 188 P2045, by closely monitoring patients after they receive the treatment. Researchers will conduct various tests and ask patients about their well-being to gather information. Additionally, the study will explore whether Rhenium Re 188 P2045 can help shrink lung cancer tumors. The trial is sponsored by Andarix Pharmaceuticals, and it was previously posted by Berlex, Inc.

Eligibility Criteria

Inclusion Criteria

  • Have a confirmed diagnosis of Non-Small-Cell Lung Cancer (NSCLC) or Small-Cell Lung Cancer (SCLC) that is advanced or has come back after treatment.
  • Have lung cancer that has either progressed after previous chemotherapy or have chosen not to undergo standard chemotherapy.
  • Have a measurable tumor that is at least 1 cm in size in an area that has not been treated with radiation, or if it is in a previously treated area, the tumor must have grown significantly (by 50% or more) and it has been more than 8 weeks since the radiation treatment.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.